IRVINE, Calif., March 7, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, today announced that management is scheduled to make an investor presentation at the ROTH Annual Growth Stock Conference on Wednesday, March 14th, at 11:00 am Pacific Time. The conference is being held March 11-14th at the Ritz-Carlton in Dana Point, California.
A live audio webcast of the presentation will be available via the Investors/Events & Presentations section of CombiMatrix's website at http://investor.combimatrix.com/events.cfm. A replay of the webcast will also be available at the CombiMatrix website.
About CombiMatrix Corporation
CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Diagnostics (CMDX), is a molecular diagnostics laboratory which offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was also the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.